Summary: A girl, aged 19 months, presented with a sacrococcygeal tumor that developed at 5 months after birth and gradually enlarged. Serum tumor marker levels were negative. Ultrasound imaging showed abundant blood flow in the tumor. However, neither computed tomography (CT) nor magnetic resonance imaging (MRI) showed contrast agent incorporation. The surgically resected tumor consisted of immature cells with myxoid stroma and proliferating small blood vessels. Immunostaining showed extensive vimentin expression. However, smooth muscle actin, muscle-specific actin, and S-100 protein expression was negative. Neither the ETV6-NTRK3 fusion gene nor the FUS gene rearrangement was detected. Thus, the patient was diagnosed with a primitive myxoid mesenchymal tumor of infancy. This tumor primarily consisted of a mucosal stroma with a low absorption on CT, a low signal on T1-weighted MRI, and a high signal on T2-weighted MRI. A diagnosis of primitive myxoid mesenchymal tumor of infancy should be considered in cases of soft tissue tumors in infants that show prominent vascularity but little contrast enhancement on MRI or CT.
Key Words: soft tissue sarcoma, primitive myxoid mesenchymal tumor of infancy, nonrhabdomyosarcoma soft tissue sarcomas (J Pediatr Hematol Oncol 2013;35:e280-e282) C hildhood soft tissue sarcomas (STSs) account for approximately 7% of all cancers in patients below 20 years of age. 1 Nonrhabdomyosarcoma soft tissue sarcomas (NRSTSs) are of different histotypes. Some histotypes are typical in infants, such as congenital infantile fibrosarcoma (CIFS), and others are typical in adults. 1 NRSTSs often develop during infancy (below 1 y of age) or in children above 8 years old. Most NRSTSs that develop during infancy are fibrosarcomas. 1 The symptoms vary because NRSTSs develop in various regions. NRSTSs are difficult to diagnose on the basis of blood tests and imaging analyses; thus, the histologic evaluations are absolutely necessary for diagnosis and planning of therapeutic approaches. Chromosomal and genetic analyses have facilitated the diagnoses of unclassifiable NRSTSs. Prognoses are generally dependent on tumor size, metastasis, histologic grade, and tumor resection. 1 Surgical resection is the first treatment of choice, regardless of the tumor type. The roles of chemotherapy and radiotherapy have not been established for many types of NRSTSs.
Herein, we report a case of primitive myxoid mesenchymal tumor of infancy (PMMTI), a rare sacrococcygeal tumor among childhood NRSTSs.
CASE REPORT
The patient was a girl, aged 19 months. She was born at 39 weeks and 1 day of gestation and her birth weight was 2900 g. No tumor was noted at birth. With regard to the patient's family history of malignant cancer, the maternal grandfather had developed stomach cancer, but no other malignancies were reported. The patient presented with a sacrococcygeal tumor that had developed at 5 months after birth and had gradually enlarged from an initial size of 1Â 1 cm. The patient was presented at our hospital at 19 months of age.
The sacrococcygeal tumor was 4Â 4.5 cm in size and with elasticity and a clear mobile margin. Neither tenderness nor redness was noted (Fig. 1A ). Blood test reports showed no elevation in the levels of serum tumor markers, including a-fetoprotein, neuron-specific enolase, and human chorionic gonadotropin. No other abnormal findings were noted. Ultrasonography (US) showed a solid tumor with a uniform, high-intensity, internal echo. Color Doppler US revealed abundant blood flow at the margin and within the tumor (Fig. 1B) . Computed tomography (CT) revealed a low-density mass without calcification along the dorsal midline of the sacrococcygeal region (Fig. 1C) . Magnetic resonance imaging (MRI) showed a welldemarcated tumor that was observed along the dorsal midline of the sacrococcygeal region; the tumor had a low internal signal on T1-weighted imaging, a high signal on T2-weighted imaging, and many low-signal lines that were presumed to represent septa (Figs. 1D-E). Neither CT nor MRI showed contrast agent incorporation. Gallium scintigraphy showed no abnormal contrast accumulation.
No diagnosis could be made on the basis of the preoperative examination, and, thus, the tumor was resected for examination and treatment. Subcutaneous tissue was observed between the tumor and skin. No skin invasion was noted. The tumor was easily resected from the skin but was firmly fixed to the muscles, sacrum (S5), and coccyx on the sacrococcygeal side. Thus, the tumor was completely resected with the coccyx.
The resected tumor was 42Â35Â30 mm in size and weighed 30 g. The tumor was almost spherical in shape, with a smooth surface before fixation that resembled a glossy, white-fleshed lychee ( Fig. 2A) . Histopathologically, a myxoid solid tumor with an invasive protrusion at the margin was visible to the naked eye. Microscopic analysis revealed immature short spindle cells with relatively mild dyskaryosis. Nearly spherical cells were observed at relatively high densities in a multinodular manner within mucosal stroma. Marked angiogenesis was noted. Nuclear division was conspicuous, although no tumor necrosis was observed (10 to 20/10 HPF; Fig. 2B ). The tumor was positive for alcian blue staining (myxoid regions) and could be digested with hyaluronan. Immunohistochemical analysis showed that the tumor was positive only for vimentin and negative for Glut-1, S-100, asmooth muscle actin, cytokeratin AE1/3, desmin, muscle-specific actin, epithelial membrane antigen, and CD34. The frequency of Ki-67 labeling was 30%.
The tumor cell karyotype was 46, XX. Fluorescence in situ hybridization analysis revealed no splits in the ETV6 or FUS gene. Further ETV6-NTRK3 fusion gene was not detected by reverse transcription polymerase chain reaction analysis. Genome array analysis revealed no alterations in the copy number, except for a loss of heterozygosity on chromosome 21 (data not shown).
The tumor was considered to be a childhood STS or CIFS because of the proliferating immature spindle cells. However, immunohistochemical analysis showed that the tumor was negative for smooth muscle actin, muscle-specific actin, and S-100 protein expression, and the ETV6-NTRK3 fusion gene was not detected. Thus, the tumor was atypical. Despite the myxoid background, the tumor was not considered to be a myxoid chondrosarcoma, because it could be digested with hyaluronan. The tumor was determined to be a PMMTI because it was composed of immature cells and exhibited considerable angiogenesis. Neither direct invasion nor distal metastasis was noted, and the tumor was completely resected. The patient did not receive postoperative chemotherapy. No recurrence was noted during the 24-month follow-up period after tumor removal.
DISCUSSION
PMMTI is a mesenchymal tumor that was recently described by Alaggio et al. 2 It is characterized by a myxoid background, the absence of the ETV6-NTRK3 fusion gene, and possible recurrence or death, unlike CIFS, which has a good prognosis. Only 11 PMMTI cases have been reported, including our case [2] [3] [4] [5] (Table 1) . On the basis of the published cases, PMMTI, a nonencapsulated tumor with a multinodular appearance, locally develops in the trunk, extremities, and head and neck regions of newborns and infants and presents with locally invasive proliferation. In particular, 4 PMMTI patients, including our patient, developed tumors in the para-axial region that did not connect with the spine and nerve, thereby excluding the possibility of a neural origin of the tumor. Age at diagnosis was before 6 months except for 2 patients. Tumor length ranged from 2 to 15 cm (median length, 5 cm). The cut surface of the tumor resembled white flesh. Pathologically, the tumor consisted of primitive spindle, pleomorphic, and nearly round cells. The cells grew in a multinodular manner and had a mucosal stroma. The periphery of the tumor showed high cell density and a delicate vascular network. Immunohistochemically, the tumor was positive for vimentin but negative for smooth muscle actin, muscle-specific actin, S-100 single membrane, and myogenin expression. Electron microscopic analysis showed the presence of proliferating undifferentiated fibroblasts. Cytogenetically, the ETV6-NTRK3 fusion gene, which is detected in CIFS, was not observed. Abnormalities of chromosomes 3, 9, and Y have been reported in PMMTI. PMMTI should be differentiated from other STSs, including rhabdomyosarcoma, CIFS, low-grade fibromyxoid sarcoma (LGFMS), and undifferentiated STS. Importantly, PMMTI should be differentiated from CIFS and LGFMS. CIFS presents with vimentin-positive spindle cells that form a herringbone pattern and the ETV6-NTRK3 fusion gene.
LGFMS is an epithelial membrane antigen-negative hyalinizing spindle cell tumor that presents with giant rosette formations and the FUS-CREB3L2 or FUS-CREB3L1 fusion gene.
Among the published cases of PMMTI, resections were performed in all cases, and chemotherapy was administered in 3 cases. Chemotherapy (vincristine, actinomycin, and cyclophosphamide) was administered to 1 patient after conservative surgery. However, radical resection was required because the tumor did not regress. 3 Chemotherapy (unspecified) was administered in recurrent or unresectable cases. It was ineffective in 1 case and abrogated liver metastasis in another case. 2 Recurrent or metastatic cases have been documented, and incomplete resection can result in recurrence within a few months. Thus, patients with PMMTI might require complete surgical excision, because the usefulness of chemotherapy might be limited.
Our case was definitively diagnosed as PMMTI on the basis of pathologic and genetic analyses. CT and MRI showed a low absorption and a high signal, respectively, on T2WI findings suggestive of a tumor with an abundant mucosa. 6 Doppler US showed abundant blood flow in the tumor, which reflected angiogenesis. It is unknown whether these findings are PMMTI specific, because no report has been published previously regarding blood flow and imaging analyses in this tumor type. PMMTI is a diagnostic consideration for soft tissue tumors of infancy that are characterized by the negative expression of tumor markers, abundant blood flow as determined by US, and a myxoid background as determined by CT/MRI without imaging effects.
The present case involved a childhood sacrococcygeal tumor. Sebire and colleagues examined 85 infant and childhood sacrococcygeal tumor cases. Of these, 93% were germ cell tumors. Sacrococcygeal tumors that develop during or after childhood might be malignant. 7 Non-germ cell sacrococcygeal tumors included mesenchymal tumors such as myxopapillary ependymomas, primitive neuroectoderma tumors, lipomatous tumors, and unclassifiable inflammatory tumors. Our case is the first to report on sacrococcygeal PMMTI. Thus, PMMTI should be considered in the differential diagnosis of childhood sacrococcygeal tumors. 
